(R)-2-Amino-3-(4-fluorophenyl)propan-1-ol | 348619-91-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-2-Amino-3-(4-fluorophenyl)propan-1-ol
• 英文别名: (2R)-2-amino-3-(4-fluorophenyl)propan-1-ol
• CAS: 348619-91-0
• 化学式: C₉H₁₂FNO
• 分子量: 169.2
• InChiKey: NHOCAYQCFORHNF-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-methylsulfanyl-5-quinolin-6-ylmethylene-thiazol-4-one 、 (R)-2-Amino-3-(4-fluorophenyl)propan-1-ol 、 N,N-二异丙基乙胺 以to give 2-[(R)-2-(4-fluoro-phenyl)-1-hydroxymethyl-ethylamino]-5-[1-quinolin-6-yl-meth-(Z)-ylidene]-thiazol-4-one的产率得到2-[(R)-2-(4-fluoro-phenyl)-1-hydroxymethyl-ethylamino]-5-[1-quinolin-6-yl-meth-(Z)-ylidene]-thiazol-4-one
  参考文献：
  名称：

  Thiazolinone unsubstituted quinolines

  摘要：

  噻唑啉酮喹啉衍生物在喹啉环上没有取代基，作为CDK1抑制剂具有活性，可用作抗增殖剂，例如用于治疗实体肿瘤。

  公开号：

  US20060004045A1
• 作为产物：
  描述：

  硼氢化钠 、 4-氟-D-苯丙氨酸 、 碘 、 甲醇 在 氢氧化钾 、 二氯甲烷 、 Sodium sulfate-III 、 Silica gel 、 甲醇 作用下， 以 四氢呋喃 为溶剂， 反应 22.5h， 以Flash chromatography (Merck Silica gel 60, 70-230 mesh, 0%-10% methanol in methylene chloride in 30 min afforded (R)-2-(4-fluoro-phenyl)-1-hydroxymethyl-ethylamine (0.73 g, 79%)的产率得到(R)-2-Amino-3-(4-fluorophenyl)propan-1-ol
  参考文献：
  名称：

  Thiazolinone unsubstituted quinolines

  摘要：

  在喹啉环上没有取代基的噻唑啉衍生物作为CDK1抑制剂具有活性，可用作抗增殖剂，例如用于治疗实体肿瘤。

  公开号：

  US07326786B2

文献信息

• Fused purine derivatives
  申请人：——

  公开号：US20030176698A1

  公开（公告）日：2003-09-18

  A condensed purine derivative represented by Formula (I): 1 wherein X—Y—Z represents R 1 N—C═O or N═C—W, R 2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted alicyclic heterocyclic group or the like, n represents an integer of from 0 to 3, V 1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, V 2 represents a substituted lower alkyl group or a substituted or unsubstituted aromatic heterocyclic group, and when V 1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and for example, X—Y—Z represents R 1a N—C═O and R 2 represents a substituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted alicyclic heterocyclic group, a halogen atom, a lower alkylthio group, —NR 7 R 8 , —CO 2 H, a lower alkoxycarbonyl group, —COHal, —CONR 9 R 10 or —CHO, V 2 may represent a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group; or a pharmacologically acceptable salt thereof.

  一个由公式(I)表示的浓缩嘌呤衍生物：1 其中，X—Y—Z代表R1N—C═O或N═C—W，R2代表氢原子、取代或未取代的低级烷基团、取代或未取代的芳烷基团、取代或未取代的芳基团、取代或未取代的芳香杂环团、取代或未取代的脂肪杂环团等，n代表从0到3的整数，V1代表氢原子、取代或未取代的低级烷基团、取代或未取代的芳烷基团、取代或未取代的芳基团或取代或未取代的芳香杂环团，V2代表取代的低级烷基团或取代或未取代的芳香杂环团，并且当V1代表氢原子、低级烷基团、取代或未取代的芳烷基团或取代或未取代的芳基团时，例如，X—Y—Z代表R1aN—C═O并且R2代表取代的低级烷基团、取代或未取代的芳烷基团、取代或未取代的脂肪杂环团、卤素原子、低级烷基亚硫酰基团、—NR7R8、—CO2H、低级烷氧羰基团、—COHal、—CONR9R10或—CHO，V2可以代表低级烷基团、取代或未取代的芳烷基团或取代或未取代的芳基团；或其药理可接受的盐。
• Azaindole thiazolinones
  申请人：Chen Shaoqing

  公开号：US20060084674A1

  公开（公告）日：2006-04-20

  Azaindole thiazolinone derivatives which demonstrate CDK1 and CDK2 antiproliferative activities and are useful as anti-cancer agents.

  Azaindole thiazolinone衍生物表现出CDK1和CDK2的抗增殖活性，并可用作抗癌剂。
• REMEDIES FOR DIABETES
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1092435A1

  公开（公告）日：2001-04-18

  A medicament for the therapeutic treatment of diabetes which comprises as an active ingredient a compound represented by the general formula (I): wherein R1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, R2 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, R3 represents a hydrogen atom, a lower alkyl group or a substituted or unsubstituted aralkyl group, X1 and X2 independently represent a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and the symbol "n" represents an integer of from 0 to 3, or a physiologically acceptable salt thereof.

  一种治疗糖尿病的药物，其活性成分包括通式(I)所代表的化合物： 其中 R1 代表氢原子、低级烷基、取代或未取代的芳基或取代或未取代的芳香杂环基团， R2 代表氢原子、低级烷基、取代或未取代的芳基、取代或未取代的芳香杂环基团、R3 代表氢原子、低级烷基或取代或未取代的芳基，X1 和 X2 独立地代表氢原子、低级烷基、取代或未取代的芳基或取代或未取代的芳基，符号 "n "代表 0 至 3 的整数，或其生理上可接受的盐。
• FUSED PURINE DERIVATIVES
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1251130A1

  公开（公告）日：2002-10-23

  A condensed purine derivative represented by Formula (I): wherein X--Y--Z represents R1N-C=O or N=C-W, R2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted alicyclic heterocyclic group or the like, n represents an integer of from 0 to 3, V1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, V2 represents a substituted lower alkyl group or a substituted or unsubstituted aromatic heterocyclic group, and when V1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and for example, X--Y--Z represents R1aN-C=O and R2 represents a substituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted alicyclic heterocyclic group, a halogen atom, a lower alkylthio group, -NR7R8, -CO2H, a lower alkoxycarbonyl group, -COHal, -CONR9R10 or -CHO, V2 may represent a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group; or a pharmacologically acceptable salt thereof.

  由式(I)代表的缩合嘌呤衍生物： 其中 X--Y--Z代表 R1N-C=O或N=C-W，R2代表氢原子、取代或未取代的低级烷基、取代或未取代的芳烷基、取代或未取代的芳基、取代或未取代的芳香杂环基团、取代或未取代的脂环杂环基团或类似基团，n代表0至3的整数，V1代表氢原子、V1 代表氢原子、取代或未取代的低级烷基、取代或未取代的芳烷基、取代或未取代的芳基或取代或未取代的芳杂环基团、V2 代表取代的低级烷基或取代的或未取代的芳杂环基团，当 V1 代表氢原子、低级烷基、取代的或未取代的芳烷基或取代的或未取代的芳基时，例如，X--Y--Z 代表 R1aN-C=O，R2 代表取代的低级烷基、取代或未取代的芳烷基、取代或未取代的脂环杂环基、卤素原子、低级烷硫基、-NR7R8、-CO2H、低级烷氧基羰基、-COHal、-CONR9R10 或 -CHO，V2 可代表低级烷基、取代或未取代的芳烷基或取代或未取代的芳基；或其药理学上可接受的盐。
• TRICYCLIC ERYTHROMYCIN DERIVATIVES
  申请人：Abbott Laboratories

  公开号：EP0961776A1

  公开（公告）日：1999-12-08